Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of irinotecan
in treating patients who have refractory metastatic breast cancer.